ISSN:
1569-8041
Keywords:
gemcitabine
;
platinum-refractory ovarian cancer
;
prognostic factors
;
quality of life
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract This phase II study evaluated the response rate and toxicity of single-agent gemcitabine in 40 women with epithelial ovarian cancer, previously treated with platinum-based chemotherapy. Patients had stage III or IV disease and progressive disease 1–12 months after the last treatment. Gemcitabine 1250 mg/m2 was administered on days 1, 8 and 15 of each 28-day cycle as a 30-minute infusion. The overall response rate to gemcitabine was 22% (95% confidence intervals: 10–39%). Responses to gemcitabine were observed in patients with platinum-refractory disease, which suggests no cross resistance to platinum. Gemcitabine was well tolerated and no grade 4 toxicity was seen. This study confirms that gemcitabine is active and well tolerated in pre-treated women with ovarian cancer.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008364327684
Permalink
